NovaBridge Biosciences (NBP)
NovaBridge Biosciences develops drug candidates for cancer and eye disease, led by givastomig for gastric cancer. It last closed at $0.82 on Nov 17, up 3.89% on the day. NBP last reported earnings on Mon, Jun 29, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From NBP's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jun 16). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Technical Analysis
The stock is 28% below its 20 day and 57% below its 50 day average. It is 145% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $0.80, and the nearest resistance the Pivot R1 at $0.85.
| RSI (14) | 24.81 | Oversold below 30 | Oversold |
| MACD | -0.15 | Below its signal line | Bearish |
| Stochastic | 9.8 | Near the bottom of its range | Oversold |
| ADX (14) | 45.0 | Strong downtrend | |
| Williams %R | -86.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -94.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −18.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.08 | Typical daily range, 9.4% of price |
| RSI (14) | 28.85 | Oversold below 30 | Oversold |
| MACD | -0.36 | Below its signal line | Bearish |
| Stochastic | 4.5 | Near the bottom of its range | Oversold |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -94.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -162.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.26 | Typical daily range, 31.1% of price |
What happened before
See how NBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NBP in the last 90 days.
NBP Institutional Ownership
Full report →- ●23 buying vs 22 selling
- ▼Shares held by funds -7.7%
- ▼Funds holding -1
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 48 | 49 | −2.0% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 9 / 14 | 13 / 13 | −11.5% |
| Reduced / sold out | 13 / 9 | 11 / 11 | 0.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBP is in one of them and how their past NBP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBP in an article yet. Here's the latest on the wider market.
About NovaBridge Biosciences
NovaBridge Biosciences is a biotechnology company based in Rockville, Maryland, that develops drug candidates for cancer and eye disease. Its lead program is givastomig, an antibody therapy being tested for gastric cancer and other tumors that express the CLDN18.2 protein. The company is also developing VIS-101, a candidate for wet macular degeneration and diabetic macular edema. Its treatments are aimed at patients worldwide.
- Headquarters
- Rockville, MD

